An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
Objective: To assess efficacy and safety of mirabegron 25 mg/day and 50 mg/day for overactive bladder in Chinese participants. Methods: Participants of ≥18 years with overactive bladder symptoms lasting for ≥12 weeks, a mean of ≥8 micturitions per 24 h, and a mean of at least one episode of Grade 3...
Saved in:
Main Authors: | Zhipeng Zhang, Deyi Luo, Zhong Chen, Peng Zhang, Ganping Zhong, Keji Xie, Zhuoqun Xu, Xudong Li, Jianye Wang, Yingfan Yang, Farid Abdul Hadi, Arianne Schild |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Asian Journal of Urology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388224000936 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder
by: Jee Soo Park, et al.
Published: (2025-01-01) -
Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01) -
Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment
by: İrfan Şafak Barlas, et al.
Published: (2024-04-01) -
Efficacy and safety of solifenacin for overactive bladder: An updated systematic review and meta-analysis
by: I Gede Yogi Prema Ananda, et al.
Published: (2025-01-01) -
The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation
by: Carlos Eduardo Rocha Macedo, et al.
Published: (2025-01-01)